Thyroid antibodies in patients with differentiated thyroid carcinoma

Thyroid antibodies have a key role in follow up of the patients with thyroid carcinoma, thus present study investigates thyroid antibodies in patients with differentiated thyroid carcinoma.

For this cross sectional study, 157 patients with differentiated thyroid carcinoma (case group) and 434 healthy subjects (control group) were included. Serum level of antithyroglubin and antiperoxidase were measured (RADIM, Italia). Antithyroglubin and antiperoxidase levels of >150u/ml and 100u/ml, respectively, were considered positive. Based on the recent intervention (surgery or radioactive iodine intake) patients were assigned in two groups of before and after 6 months and the aforementioned antibodies were checked.

The mean (±standard deviation) of antithyroglubin was 290±111 and 405±111 u/ml in case and control group, respectively. The mean antiperoxidase level was 257±46 and 302±73u/ml, respectively. positive antithyroglubin level was reported in 21(13.4%) cases versus 65(15%) controls (NS), however, positive antiperoxidase level was found in 6(3.8%) cases and 42(9.7%) controls (p=0.02).

Patients with thyroid carcinoma showed similar antithyroid antibodies as healthy population, however, their level within the first 6-month following the intervention was significantly higher than 6 months after the intervention.